- Healthcare 150
- Posts
- FDA Breakthrough, $5.9B Lilly Deal & Healthcare’s Margin Squeeze
FDA Breakthrough, $5.9B Lilly Deal & Healthcare’s Margin Squeeze
Healthcare's next competitive advantage isn't innovation. It's execution.

Good morning, ! Today we’re diving into healthcare’s growing execution gap and the push for measurable performance, the FDA’s breakthrough in stroke prevention, Nanopath’s $25 million bet on rapid molecular diagnostics, and the latest wave of billion-dollar pharma and biotech deals.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team

DATA DIVE
Healthcare's Execution Gap: Why Performance Is the New Growth
Healthcare's next competitive advantage isn't innovation. It's execution.
Across four Healthcare150 Micro Surveys, a consistent pattern emerges: 48% of respondents identify labor productivity as the biggest hospital margin opportunity, while 29% see operating margin as the KPI investors will watch most closely.

But the real problem is alignment. 54% of clinical leaders prioritize workforce productivity, while 56% of IT executives focus on financial performance and revenue cycle. Different departments, different priorities, same hospital.
Digital health faces a similar challenge. 39% of respondents identify navigating health systems as the biggest barrier to enterprise scale, ahead of unclear clinical ROI (31%) and reimbursement (30%).
Meanwhile, hospital expenses rose 7.5% in 2025, more than double hospital price growth (3.3%), according to the AHA.
Why it matters: For operators and investors, the opportunity is shifting from expanding capabilities to converting them into measurable financial outcomes. Technology adoption, workforce optimization, and revenue growth mean little without demonstrable margin improvement.
Finally, a Monday that doesn’t feel like one.
Imagine a Saturday where you're not catching up on the CRM you didn't touch all week.
HubSpot's new self-updating CRM doesn't wait for you to log back in. Friday's calls are already logged. The deal that needs a nudge Monday morning is already flagged. The automation you set up once keeps running without you thinking about it. None of it needed you over the weekend.
Customers are already seeing it pay off: 45% more deals closed. Finally, you start Monday caught up, not behind.

HEADLINE OF THE WEEK
FDA Approves First-of-Its-Kind Blood Thinner: A New Era in Stroke Prevention Begins
So What? Bayer's landmark approval of Sunharbo (asundexian), which reduced recurrent ischemic stroke risk by 26% in a Phase III trial involving more than 12,000 patients, opens a new therapeutic category in cardiovascular medicine, potentially reshaping the competitive landscape for anticoagulants and creating a significant commercial opportunity for next-generation stroke prevention. (More)

COMPANY OF THE WEEK
Nanopath
Bringing molecular testing closer to the patient
Cambridge, Massachusetts-based Nanopath is developing a 15-minute, point-of-care test for vaginitis, aiming to give clinicians molecular diagnostic results during a single visit rather than sending samples to a centralized laboratory.
On November 10, 2026, the company announced a $25 million financing package, including $2 million in non-dilutive grants. The Series B was co-led by Norwest and SV Health Investors’ MedTech Convergence Fund, with strategic participation from the Labcorp Venture Fund. The capital will support manufacturing scale-up, initiation of a clinical study to support an FDA 510(k) submission, and expansion of its clinical and commercial teams.
Nanopath’s optical biosensing technology is designed to detect molecular targets without the nucleic acid amplification step used in PCR testing. If clinically validated and cleared, that approach could help clinicians make treatment decisions before patients leave the office. The company also sees potential applications in urinary tract and sexually transmitted infections.
The milestone is funding for development, not regulatory clearance: the vaginitis test remains under development and has not been FDA-cleared or approved. Its proposed speed and clinical benefits still require validation. (More)

DEALS TRACKER
Eli Lilly → Stipple Bio | Up to $5.9B in milestones + upfront and equity investment
Lilly signed an oncology research and licensing deal with Stipple Bio, gaining exclusive worldwide rights to products developed through the collaboration. Read more
Johnson & Johnson → Ollin Biosciences | $2.2B upfront + ~$1.1B in milestones
J&J agreed to acquire Ollin Biosciences, adding a Phase 3 antibody for wet age-related macular degeneration and diabetic macular edema. Read more
Novartis → OBI Pharma ADC platform | $30M upfront; >$2B total potential value
Novartis signed a collaboration and licensing agreement for OBI’s antibody-drug conjugate technologies, expanding its oncology capabilities with selected payload classes and an option to broaden the partnership. Read more
Eli Lilly → Calytrix Bio | Up to $1.5B, including milestones
Lilly agreed to acquire Calytrix Bio, adding a preclinical antibody targeting mutant calreticulin for essential thrombocythemia and myelofibrosis. Read more
Sanofi → Seawolf Therapeutics | Up to $1.2B in milestones + royalties
Sanofi entered a research collaboration and exclusive licensing agreement with Seawolf to develop DNA-based medicines for bleeding disorders and other indications using its TRIDENT delivery platform. Read more

INTERESTING ARTICLES






